Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00884182
Other study ID # GPA12
Secondary ID
Status Completed
Phase Phase 2
First received April 16, 2009
Last updated January 10, 2014
Start date April 2009
Est. completion date June 2010

Study information

Verified date January 2014
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority Finland: Finnish Medicines Agency
Study type Interventional

Clinical Trial Summary

This study is part of an effort to develop an effective vaccination program in children in the event of a pandemic.

Study objectives:

- To describe the safety profiles in the periods following each vaccination in subjects receiving different vaccination schedule.

- To describe the immune response after each vaccination in subjects receiving study vaccine.


Description:

Study participants will receive two administrations of the investigational vaccine at one of 3 vaccination schedules.


Recruitment information / eligibility

Status Completed
Enrollment 350
Est. completion date June 2010
Est. primary completion date March 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 6 Months to 17 Years
Eligibility Inclusion Criteria :

All Subjects

- Subject and parent(s)/legal representative able to attend all scheduled visits and to comply with all trial procedures.

- Completion of vaccination according to the national immunization schedule

Subjects Aged = 2 Years to < 18 Years:

- Aged = 2 years to < 18 years on the day of inclusion.

- Provision of Informed Consent Form signed by the subject's the parent(s)/legal representative (and by an independent witness if required by local regulations). In addition, provision of Assent Form signed by subjects aged 8 to 11 years, and of Informed Consent Form signed by subjects = 12 years.

- For a female of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to each vaccination, until at least 4 weeks after each vaccination.

Subjects Aged = 6 Months to < 2 Years:

- Aged = 6 months to < 2 years on the day of inclusion.

- Born at full term of pregnancy (= 37 weeks) with a birth weight = 2.5 kg.

- Provision of Informed Consent Form signed by the parent(s) or other legal representative (and by an independent witness if required by local regulations).

Exclusion Criteria :

All subjects

- Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding trial vaccination

- Planned participation in another clinical trial during the present trial period

- Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy

- Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances

- Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator

- Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures

- Receipt of Blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response

- Receipt of any vaccine in the 4 weeks preceding trial vaccination

- Planned receipt of any vaccine in the 4 weeks following any trial vaccination

- (Known) Human Immunodeficiency Virus (HIV), Hepatitis B surface (HBs) antigen or Hepatitis C seropositivity

- Previous vaccination against avian influenza with either the trial vaccine or another vaccine

- Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination

- Subjects deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent

- Received oral or injected antibiotic therapy within the 72 hours prior to any blood draw

Subjects Aged =2 Years to <18 Years:

- For a female of child-bearing potential, known pregnancy or positive urine pregnancy test

- Breast-feeding female

- Febrile illness (temperature = 37.5 °C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment

Subjects Aged = 6 Months to < 2 Years:

- History of seizures

- Febrile illness (temperature = 38 °C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Biological:
A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
0.5 mL, Intramuscular

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary To provide information concerning the safety of the Split Virion Pandemic Influenza vaccine. 21 days post-vaccination and entire study Yes
Secondary To provide information concerning the immunogenicity of Split Virion Pandemic Influenza vaccine. 21 days post-vaccination No
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A

External Links